Benefit of pegylated interferon-alpha-2a/ribavirin in a patient with common variable immunodeficiency and hepatitis C virus cirrhosis after liver transplantation and splenic embolization.
Foruny
José R
JR
Bárcena
Rafael
R
Moreno
Ana
A
Blázquez
Javier
J
Manzano
Rebeca
R
Gil-Grande
Luis A
LA
Moreno
Alberto
A
Nuño
Javier
J
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D006526:Hepatitis C / Q000188:drug therapy* / Q000601:surgery*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007153:Immunologic Deficiency Syndromes / Q000188:drug therapy*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000276:immunology*; D008297:Male; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome; D019562:Viral Load
D000998:Antiviral Agents; D007074:Immunoglobulin G; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a